MedInCell Stock Drops 3.61% and Tests a Critical Technical Threshold
On Tuesday, April 28, 2026, shares of the Montpellier-based biotech company fell by 3.61%, closing at 22.94 euros. This decline extends a challenging week for MedInCell, with the stock losing about 4% over the past seven days, amidst a session where the CAC 40 gained 0.36%.
A Stock Under Pressure Testing Sensitive Technical Levels
At 22.94 euros, MedInCell is trading nearly at its 50-day moving average of 22.93 euros, a threshold that serves as a pivotal short-term zone. The price is significantly below the 200-day moving average, which stands at 24.03 euros, indicating a still fragile underlying trend despite an impressive annual performance of over 53%. Concurrently, the RSI at 49 signals a neutral situation, with no excess selling or demand, leaving the stock in a zone of indecision. The Bollinger Bands confirm this intermediate positioning: the price is in the lower part of the band, 40% between the floor (21.31 euros) and the ceiling (25.35 euros). Should selling pressure continue, the next identified technical support is at 20.24 euros, representing a potential further decline of about 12% from the current level.
A Financial Calendar to Watch in a Mixed Sector
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The next key event for the company is the announcement of its annual results for the 2025-2026 fiscal year, scheduled for Tuesday, June 16, 2026. This potential catalyst could help clarify the stock's trajectory after a quarter of decline: over three months, the stock has fallen by more than 17%. The general assembly is set for Thursday, September 10, 2026. In Europe, the pharmaceutical sector shows mixed dynamics in this Tuesday's session. Sanofi is up 0.51%, while UCB is down 4.58%. Across the Atlantic, major names in the sector are in negative territory at the day's close: Eli Lilly is down 1.77%, Johnson & Johnson is down 0.95%, and AbbVie has fallen by 0.67%. However, MedInCell's low beta of 0.19 reminds us that the stock maintains a limited correlation with major indices, its performance being more closely tied to its own fundamentals and the progress of its portfolio of extended-release technologies.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
